Sp110
TRANSLATING EVIDENCE INTO QUALITY IN INFLAMMATORY BOWEL DISEASE
Date
May 6, 2023
Explore related products in the following collection:
Tracks
Related Products
Q&A
This session is designed to demonstrate successful quality improvement in practices and across institutions with the focus on and meaningful real world implementation across a range of GI conditions…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
CLINICAL, SEROLOGIC, AND GENETIC FACTORS ASSOCIATED WITH DECREASED POST-OPERATIVE PROPHYLAXIS PERSISTENCE IN CROHN’S DISEASE (CD)
BACKGROUND: Cancer is a major cause of morbidity and mortality in persons with inflammatory bowel disease (IBD). We evaluated temporal trends and relative risks of intestinal and extra-intestinal cancers among persons with IBD and matched controls…